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Pedersen et al Session I: Lung Cancer Diagnosis and StagingLung cancer screening trials: Denmark and beyondJesper H. Pedersen, MD, DMsci, Rene H. Petersen, MD, and Henrik J. Hansen, MDLung cancer is the leading cause of cancer death worldwide,
with fewer than 15% of patients surviving 5 years after di-
agnosis, despite advances in treatment during the past 20
years. Lung cancer screening (secondary prevention), in ad-
dition to smoking cessation programs (primary prevention),
might be the most exciting improvement in methods to re-
duce lung cancer mortality. The great interest in lung cancer
screening was started by the introduction of low-dose multi-
detector computed tomography (CT) in the 1990s. The non-
randomized International Early Lung Cancer Action
Project study (n ¼ 32,000)1 was followed by several ran-
domized clinical trials of high-risk current and former
smokers. These included the National Lung Screening Trial
(NLST) in the United States (n ¼ 53,500),2 the Dutch-
Belgian screening trial (n¼ 15,822),3 the Danish Lung Can-
cer Screening Trial (DLCST, n¼ 4104 ),4 and several other
collaborating trials in Europe.5-7 Recently, the National
Cancer Institute published the report that the NLST gave
evidence for a mortality reduction of 20.3% with low-dose
CT screening compared with chest radiographic screening
and a 7% overall mortality reduction after 3 annual screen-
ing rounds and 8 years of follow-up.2 The NLSTwas a very
well-performed randomized trial and has convincingly
shown for the first time that CT screening, in high-risk sub-
jects, can lead to a substantial reduction in lung cancer mor-
tality and that the screening overall was not detrimental,
because a reduction of 7% in general mortality was also ob-
served. These are extremely important findings. The Euro-
pean trials have been smaller, but all have had a control
group without any screening performed (usual care) and,
therefore, potentially, the difference between the mortality
in the CTand control arms could bemore pronounced. In ad-
dition, the trials were started 2 to 3 years after the NLSTand,
therefore, have not yet performed a pooling of data and pre-
sented a combined mortality analysis. The Dutch-Belgian
screening trial and theDLCSTare expected to perform afinal
mortality analysis in 2015 but contemplated a preliminary
pooling of data in 2011.From the Department of Thoracic Surgery RT, Rigshospitalet, University of Copen-
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The Journal of Thoracic and CThe DLCST is a 5-year prospective randomized con-
trolled screening trial evaluating the effect of annual CT
screening for lung cancer. The overall design and baseline
results were published in 2009.4METHODS
FromOctober 2004 toMarch 2006, 4104men andwomenwere enrolled
in the DLCST after recruitment by advertisements in local and regional
free-of-charge newspapers, stating the purpose, study design, and inclusion
criteria. The trial was funded in full by a governmental grant and was
without costs to the participants.
The inclusion criteria were men (55%) and women (45%), aged 50 to
70 years, whowere current or former smokers with at least 20 pack-years of
smoking history. Former smokers should have quit for no more than 10
years. Lung function was measured by spirometry and forced expiratory
volume in 1 second had to be at least 30% of predicted.
The exclusion criteria were a body weight greater than 130 kg, a history
of cancer diagnosis and treatment, lung tuberculosis, expected life expec-
tancy of less than 10 years, and chest CT scan received during the past year
for any reason.
Randomization was to either a screening group (n ¼ 2052) or a control
group (n ¼ 2052). The screening group received 5 annual, low-dose chest
CT scans (1 baseline scan and 4 incidence scans). All came for an annual
visit to the screening clinic, at which lung function tests were performed
and questionnaires concerning health, lifestyle, smoking habits, and psy-
chosocial consequences of screening were completed.1 The CT scans
were evaluated by 2 experienced radiologists,1 with volumetric analysis
of the detected nodules validated as in the Dutch-Belgian screening trial.8
Positron emission tomography scans were used to supplement the radio-
logic assesment.9RESULTS
The DLCST showed that smoking habits during screen-
ing were unaffected by CT screening per se at 1 year of
follow-up.10 Contamination by off-study CT scans in the
control group was low (0.04%).11
In the CT screening group, a total of 68 lung cancers were
diagnosed. At baseline, the detection rate was 0.8%,4 and
the incidence rounds had a mean annual detection rate of
0.6% (chi-square test, P ¼ .492). Of the 68 cases, 3 were
small cell lung cancer (SCLC) and 65 were non–SCLC.
Also, 57 (84%) were early stage (stage I–IIIA non–SCLC
and limited-stage SCLC) and thus potentially curable, and
11 (16%) were diagnosed in a late stage (stage IIIB–IV
non–SCLC and extensive-stage SCLC). One interval cancer
was diagnosed 10 months after the third incidence scan.
Significantly more lung cancers were diagnosed in the
screening group (chi-square test, 68 vs 24; P< .001) and
more were low stage (chi-square test, 57 vs 10; P<.001).
The number of late-stage lung cancers was the same in
both groups (chi-square test, 11 vs 14; P¼ .640). The num-
ber of new lung cancers remained high during all 4 inci-
dence rounds in the screening group compared withardiovascular Surgery c Volume 144, Number 3 S7
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screen-detected lung cancers (>75%) were treated by min-
imally invasive surgery (video-assisted thoracic surgery;
data to be published).CONCLUSIONS
The experience from the lung cancer CT screening trials
have shown that CT screening will lead to increased detec-
tion of early-stage lung cancer and, consequently, an in-
creased number of early-stage cases will be referred for
surgical treatment. Most of these cases will be suitable for
minimal invasive treatment. It is important that surgeons
prepare themselves for this scenario, to deliver high-
quality minimally invasive surgery to their patients, when-
ever appropriate.References
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